State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The company has already embarked upon significant expansion in Turkey
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company plans to enter the EU markets in FY22
Subscribe To Our Newsletter & Stay Updated
